战略与国际研究中心-National-Developments-of-Biological-Weapons-in-the-Middle-East_35页_160kb

报告摘要

Summary of National Developments of Biological Weapons in the Middle East

Core Content

This document provides an analytical overview of the development and proliferation of biological weapons in key Middle Eastern countries, particularly focusing on Iraq, Syria, Iran, and others. It discusses the capabilities, activities, and intentions of these nations in relation to biological warfare, including research, production, and potential deployment of such weapons.

Main Countries and Their Biological Weapons Activities

Algeria

Some research activity is suspected.
No evidence of production capability.

Libya

Acceded to the Biological and Toxin Weapons Convention (BWC) in 1982.
No evidence of production capability.
Engaged in extensive research efforts.

Egypt

Research and technical base are present.
US intelligence suggests no major organized production or deployment activity.
Israeli sources indicate possible development of agents such as plague, botulism toxin, encephalitis virus, anthrax, Rift Valley fever, and mycotoxicosis.
Egypt has signed but not ratified the BWC.
US believes Egypt may have developed BW agents by 1972, and capability may still exist.

Israel

Has not signed the BWC.
Has a major research facility at the Israel Institute for Biological Research (IIBR) in Nes Tona.
The facility is believed to have the capacity to produce chemical and biological weapons.
It has been reported to have stockpiled anthrax and provided toxins for covert operations.
There is speculation that Israel has more advanced biological agents than anthrax.
Uncertainty exists over whether these weapons are actively deployed.

Syria

Signed but not ratified the BWC in 1972.
Engaged in extensive research and has a large pharmaceuticals industry that could be converted for CBW production.
Has several dual-use sites, including a pharmaceutical plant in Aleppo.
Suspected of developing anthrax and botulism, possibly other agents.
Has attempted to acquire dual-use biotech equipment from Europe and Asia.
Has been linked to the development of biological variations on ZAB and PTAB bombs, and Scud warheads.
Possesses the capability to design biological warheads for missiles and aircraft.
Has a significant biomedical and industrial base, with state control over key companies.

Iran

Has extensive laboratory and research capabilities.
Biological weapons program began during the Iran-Iraq War.
Acquired type cultures from Europe and other countries.
Conducted research on anthrax, botulism, aflatoxin, and other agents.
Acquired advanced biological weapons technology from Switzerland and containment equipment from Germany.
Has been reported to have stockpiled anthrax and botulinum.
Acquired dual-use biotech equipment from Russia and other countries.
Has a significant capacity for domestic production of biological agents.
The CIA reported that Iran may have begun active production in 1996, but likely at a limited scale.
Claims of abandoning BW programs are unconfirmed.

Iraq

Had a highly compartmented "black" program with strict security measures.
Maintained 18 major sites for biological weapons efforts before the Gulf War.
Systematically lied about its BW program until 1995.
Admitted to a major defensive effort in July 1995 and a major weaponization effort in October 1995.
Continued to lie about its BW program after 1995, claiming destruction of weapons and limited involvement.
Imported 39 tons of growth media from European firms, with some unaccounted for.
Imported type cultures from the US for BW development.
Manufactured various biological agents including anthrax, botulism toxin, aflatoxin, and others.
Weaponized at least three biological agents for use in the Gulf War.
Produced 191 bombs and 25 missile warheads with biological agents.
Developed and deployed 166 R-400 bombs with biological agents.
Filled at least 25 Scud missile warheads with biological agents.
Developed drop tanks for aircraft capable of dispersing 2,000 liters of anthrax.
Conducted field trials using Mirages and other aircraft.
Retains the technology and may still be engaged in BW research and development despite UN sanctions.

Key Information

BWC Compliance: Several countries (Egypt, Libya, Syria, Iran) have signed but not ratified the BWC.
Dual-Use Facilities: Many countries have dual-use facilities that could be converted for biological weapons production.
Technological Capabilities: Iraq, Syria, and Iran are believed to have the technical infrastructure and equipment to develop and weaponize biological agents.
Weapons Systems: Biological agents can be delivered via missiles, aircraft, and other systems.
Uncertainty and Verification: There is significant uncertainty about the actual capabilities and stockpiles of biological weapons due to lack of transparency and verification.
Covert Activities: Israel and Syria are suspected of covert use of biological agents for operations and intelligence activities.
UN and UNSCOM Reports: The UN and UNSCOM have raised concerns about the credibility of declarations and the ongoing nature of BW programs in Iraq and other countries.

Conclusion

The proliferation of biological weapons in the Middle East is a complex and multifaceted issue. While some countries have formally declared their BW programs, others have been accused of covert development and use. The region's capacity for biological warfare is influenced by its scientific infrastructure, international technology transfers, and the dual-use nature of many facilities and equipment. The lack of transparency and verification has led to significant uncertainty about the actual extent of these programs.

展开完整摘要